<DOC>
	<DOC>NCT00419744</DOC>
	<brief_summary>The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.</brief_summary>
	<brief_title>A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>A current clinical diagnosis of COPD with COPD symptoms for more than 2 years Current smoker or smoking history of 10 or more pack years (1 pack year = 20 cigarettes smoked per day for one year) A history of at least 1 COPD exacerbations requiring a course of steroids and/or antibiotics within 112 months before the first visit A history of asthma at or after 18 years of age A history of allergic rhinitis at or after 18 years of age Subjects taking oral steroids Any significant disease or disorder that may jeopardize a subject's safety</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>COPD</keyword>
</DOC>